CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 14.68 HKD -3.17%
Market Cap: 8.4B HKD

CARsgen Therapeutics Holdings Ltd
Investor Relations

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Show more
Loading
2171
Hang Seng (Hong Kong)

Earnings Calls

No Earnings Calls Available

Management

Dr. Zonghai Li M.D., Ph.D.
Co-Founder, CEO, Chief Scientific Officer & Chairman of the Board
No Bio Available
Dr. Huamao Wang Ph.D.
Co-Founder, COO & Executive Director
No Bio Available
Dr. Hua Jiang
Executive Director
No Bio Available
Dr. Hong Ma
Senior Vice President of Clinical Development
No Bio Available
Dr. Leigh Hsu
Senior Vice President of Business Development
No Bio Available
Dr. Raffaele Baffa M.D., Ph.D.
Chief Medical Officer
No Bio Available
Dr. Sylvie Peltier
Senior Vice President of Global Regulatory Affairs
No Bio Available
Mr. Wing Yat Lui
Company Secretary
No Bio Available

Contacts

Address
SHANGHAI
Shanghai
Building 12, No.388 Yindu Road, Xuhui District
Contacts